There's been an all-out push by the drug regulators and media to get every adult and child on Ozempic, a drug which causes temporary weight loss and harms the majority of recipients. Here, two leading ...

It has been a rough few seasons for Novo Nordisk (NYSE:NVO) investors, as the company’s share price has tumbled some 60% over ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Once seemingly unstoppable, Novo Nordisk ($NVO) stock is now caught in a storm. Fierce competition in the GLP-1 ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Today’s Forbes Daily covers Eli Lilly’s historic loss, the new GPT-5 for OpenAI’s ChatGPT, reactions to Instagram’s new map ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with ...

Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance.

Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...